This is important because improving SMN2 exon 7 inclusion is a goal of therapeutic strategies to treat patients with spinal muscular atrophy, which is caused by defects in the SMN1 gene resulting in SMN protein deficiency. This evidence concerns the gene SMN2 and spinal muscular atrophy.